Bayer

The partners have been working together since 2013 to use cancer and cardiovascular genomics for drug discovery.

The Boston-based synthetic biology company will use the proceeds to grow Bioworks3, its new organism foundry, and to expand into new markets.

Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.

Both deals should advance Ginkgo's custom microbe business as it expands into consumer goods markets such as cosmetics, nutrition, and food.

Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.

The deal gives Bayer access to the T2 Magnetic Resonance technology for drug discovery and biomarker research in certain hemostasis programs.

The deal with ERS Genomics, a commercialization vehicle for Emmanuelle Charpentier's patents, gives the Bayer LifeScience Center access to CRISPR/Cas9 genome editing.

The company's Avatar platform cultures and propagates a variety of cell types in an in vivo-like environment to yield more accurate and relevant molecular analyses.

The JV will be based in London with operations in Cambridge, Massachusetts and will develop new treatments for blood disorders, blindness, and congenital heart disease.

The deal expands one reached in 2013 to discover and develop therapeutic agents targeting cancer genome alterations. 

Pages

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.